 The objective is to evaluate whether once weekly subcutaneous SC injection of idrabiotaparinux sodium biotinylated idraparinux is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio INR adjusted-dose warfarin in patients with atrial fibrillation AF. 